Literature DB >> 33031592

Risk-adapted therapy in follicular lymphoma: Is it time to "FLEX"?

Joshua W D Tobin1,2, Maher K Gandhi1,2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 33031592      PMCID： PMC7756717          DOI： 10.1002/ajh.26016

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  10 in total

1.  Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.

Authors:  Antoine Italiano; Jean-Charles Soria; Maud Toulmonde; Jean-Marie Michot; Carlo Lucchesi; Andrea Varga; Jean-Michel Coindre; Stephen J Blakemore; Alicia Clawson; Benjamin Suttle; Alice A McDonald; Mark Woodruff; Scott Ribich; Eric Hedrick; Heike Keilhack; Blythe Thomson; Takashi Owa; Robert A Copeland; Peter T C Ho; Vincent Ribrag
Journal:  Lancet Oncol       Date:  2018-04-09       Impact factor: 41.316

Review 2.  From genetics to the clinic: a translational perspective on follicular lymphoma.

Authors:  Sarah Huet; Pierre Sujobert; Gilles Salles
Journal:  Nat Rev Cancer       Date:  2018-02-09       Impact factor: 60.716

3.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Authors:  Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

Review 4.  The landscape of new drugs in lymphoma.

Authors:  Anas Younes; Stephen Ansell; Nathan Fowler; Wyndham Wilson; Sven de Vos; John Seymour; Ranjana Advani; Andres Forero; Franck Morschhauser; Marie Jose Kersten; Kensei Tobinai; Pier Luigi Zinzani; Emanuele Zucca; Jeremy Abramson; Julie Vose
Journal:  Nat Rev Clin Oncol       Date:  2016-12-29       Impact factor: 66.675

5.  Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.

Authors:  Michael R Green; Shingo Kihira; Chih Long Liu; Ramesh V Nair; Raheleh Salari; Andrew J Gentles; Jonathan Irish; Henning Stehr; Carolina Vicente-Dueñas; Isabel Romero-Camarero; Isidro Sanchez-Garcia; Sylvia K Plevritis; Daniel A Arber; Serafim Batzoglou; Ronald Levy; Ash A Alizadeh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

6.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Authors:  Alessandro Pastore; Vindi Jurinovic; Robert Kridel; Eva Hoster; Annette M Staiger; Monika Szczepanowski; Christiane Pott; Nadja Kopp; Mark Murakami; Heike Horn; Ellen Leich; Alden A Moccia; Anja Mottok; Ashwini Sunkavalli; Paul Van Hummelen; Matthew Ducar; Daisuke Ennishi; Hennady P Shulha; Christoffer Hother; Joseph M Connors; Laurie H Sehn; Martin Dreyling; Donna Neuberg; Peter Möller; Alfred C Feller; Martin L Hansmann; Harald Stein; Andreas Rosenwald; German Ott; Wolfram Klapper; Michael Unterhalt; Wolfgang Hiddemann; Randy D Gascoyne; David M Weinstock; Oliver Weigert
Journal:  Lancet Oncol       Date:  2015-08-06       Impact factor: 41.316

7.  Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.

Authors:  Florian Scherer; David M Kurtz; Aaron M Newman; Henning Stehr; Alexander F M Craig; Mohammad Shahrokh Esfahani; Alexander F Lovejoy; Jacob J Chabon; Daniel M Klass; Chih Long Liu; Li Zhou; Cynthia Glover; Brendan C Visser; George A Poultsides; Ranjana H Advani; Lauren S Maeda; Neel K Gupta; Ronald Levy; Robert S Ohgami; Christian A Kunder; Maximilian Diehn; Ash A Alizadeh
Journal:  Sci Transl Med       Date:  2016-11-09       Impact factor: 17.956

8.  Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network.

Authors:  A Smith; S Crouch; S Lax; J Li; D Painter; D Howell; R Patmore; A Jack; E Roman
Journal:  Br J Cancer       Date:  2015-03-24       Impact factor: 7.640

9.  Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.

Authors:  Joshua W D Tobin; Colm Keane; Jay Gunawardana; Peter Mollee; Simone Birch; Thanh Hoang; Justina Lee; Li Li; Li Huang; Valentine Murigneux; J Lynn Fink; Nicholas Matigian; Frank Vari; Santiyagu Francis; Robert Kridel; Oliver Weigert; Sarah Haebe; Vindi Jurinovic; Wolfram Klapper; Christian Steidl; Laurie H Sehn; Soi-Cheng Law; Michelle N Wykes; Maher K Gandhi
Journal:  J Clin Oncol       Date:  2019-08-28       Impact factor: 44.544

10.  Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.

Authors:  Farheen Mir; Federico Mattiello; Andrew Grigg; Michael Herold; Wolfgang Hiddemann; Robert Marcus; John F Seymour; Christopher R Bolen; Andrea Knapp; Tina Nielsen; Carla Casulo
Journal:  Am J Hematol       Date:  2020-09-16       Impact factor: 10.047
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.